Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 529

Sort by

Sort Order Select

Journal Articles

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Blood (2020) 135 (10): 735–742.

https://doi.org/10.1182/blood.2019003127

Published: 2020

Includes: Supplemental data

Journal Articles

Patterns of Care and Predictors of Survival in Adolescents and Young Adults with Hodgkin Lymphoma: A Population-Based Study

Justine M. Kahn, MD MS, Fran Maguire, PhD MPH, Qian Li, MS, Elysia Alvarez, MD MPH, Theresa H.M. Keegan, PhD MS

Blood (2019) 134 (Supplement_1): 2191.

https://doi.org/10.1182/blood-2019-129301

Published: 2019

Journal Articles

Health-Related Quality-of-Life Outcomes in Patients with Classical Hodgkin Lymphoma: A Prospective, Observational Study in US Oncology Practices

Jakub Svoboda, MD, Philippe Armand, MD PhD, Fiona Taylor, Xiaowu Sun, Alejandro Moreno-Koehler, Srikanth Gajavelli, MD, Derek Peterson, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 2192.

https://doi.org/10.1182/blood-2019-123980

Published: 2019

Journal Articles

Late Effects Are Important Considerations in Initial Hodgkin Lymphoma Treatment Decision-Making According to Survivors

Anita J Kumar, MDMS, Rachel Murphy-Banks, MA, Ruth Ann Weidner, MBA, MRP, Susan K Parsons, MD MRP

Blood (2019) 134 (Supplement_1): 2137.

https://doi.org/10.1182/blood-2019-124481

Published: 2019

Journal Articles

Exploring the Potential of Shallow Whole-Genome Sequencing for Diagnosis and Disease Monitoring of Lymphoma in Liquid Biopsy

Lennart Raman, MSc, Malaïka Van Der Linden, MSc, Ciel De Vriendt, Bliede Van Den Broeck, MD, Kristoff Muylle, MD, Dries Deeren, MD PhD, Bjorn Menten, PhD, Fritz Offner, MD, Jo Van Dorpe, MD PhD

Blood (2019) 134 (Supplement_1): 2087.

https://doi.org/10.1182/blood-2019-131391

Published: 2019

Journal Articles

Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach

Phoebe Tsz Man Cheng, BSc,MD, Diego Villa, MD MPH, R. Petter Tonseth, MD, David W. Scott, MBChB, PhD, Alina S Gerrie, MD MPH, Ciara L Freeman, MSc, MBBChir, Christina Aquino Parsons, MD, Tom Pickles, MD, Andrea Lo, MD, Don Wilson, MD, Brian Skinnider, MD, Laurie H Sehn, MD, Joseph M Connors, MD, Kerry J Savage, BSc, MD MSc

Blood (2019) 134 (Supplement_1): 2845.

https://doi.org/10.1182/blood-2019-122019

Published: 2019

Journal Articles

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Paul J. Hampel, MD, Timothy G. Call, MD, Sara J. Achenbach, Kari G Rabe, Wei Ding, MD PhD, Eli Muchtar, MD, Saad S. Kenderian, MD, Yucai Wang, MD PhD, Amber Koehler, PA-C, MS, Amie Fonder, PA-C, MS, Jose F. Leis, MD PhD, Susan M. Schwager, Daniel L. Van Dyke, PhD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Sameer A. Parikh, MD

Blood (2019) 134 (Supplement_1): 3050.

https://doi.org/10.1182/blood-2019-125411

Published: 2019

Journal Articles

A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 2834.

https://doi.org/10.1182/blood-2019-123150

Published: 2019

Journal Articles

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

Judah Friedman, MD, Hun Ju Lee, MD, Linda Ho, Ian W. Flinn, MD PhD

Blood (2019) 134 (Supplement_1): 2836.

https://doi.org/10.1182/blood-2019-122969

Published: 2019

Journal Articles

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Cédric Rossi, MD PhD, Marc André, Clémentine Joubert, PhD, Catherine Fortpied, Pauline Brice, Bénédicte Deau-Fisher, MD, Herve Ghesquieres, MD PhD, Luc Mathieu Fornecker, MD PhD, Anne-Claire Gac, MD, Julien Lazarovici, Aspasia Stamatoullas, MD, John Raemakers, Massimo Federico, MD, Marie Maerevoet, MD, Sarah Bailly, MD, Salim Kanoun, MD, Michel Meignan, Anne Ségolène Cottereau, Rene-Olivier Casasnovas, MD

Blood (2019) 134 (Supplement_1): 128.

https://doi.org/10.1182/blood-2019-125976

Published: 2019

Journal Articles

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

Blood (2019) 134 (Supplement_1): 130.

https://doi.org/10.1182/blood-2019-126787

Published: 2019

Journal Articles

Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study

Aspasia Stamatoullas, MD, Herv Ghesquieres, Lauriane Clement filliatre, MD, Philippe Quittet, MD, Franck Morschhauser, MD, Vincent Ribrag, MD, Veronique Edeline, MD, Pauline Brice

Blood (2019) 134 (Supplement_1): 132.

https://doi.org/10.1182/blood-2019-123925

Published: 2019

Journal Articles

Impact of Competing Treatment Scenarios on Lifetime Disease Burden and Quality Adjusted Life Expectancy (QALE) Among Survivors of High-Risk Childhood Hodgkin Lymphoma (HR-HL): A Modeling Study Based on the St. Jude Lifetime (SJLIFE) Cohort

Nickhill Bhakta, Kalatu Davies, PhD, Jesse Turner, PhD, Yichen Chen, PhD, Jaime Flerlage, MD MS, I-Chan Huang, PhD, Melissa M. Hudson, MD, John T. Lucas, Jr., MD MS, Monika Metzger, MD, Leslie L. Robison, PhD, F. Lennie Wong, PhD

Blood (2019) 134 (Supplement_1): 267.

https://doi.org/10.1182/blood-2019-124907

Published: 2019

Journal Articles

Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT?

Eldad J Dann, MD, Rebeca Lopez-Alonso, Shunan Qi, Tania Mashiach, Michal Weiler-Sagie, Joachim Yahalom, MD

Blood (2019) 134 (Supplement_1): 4051.

https://doi.org/10.1182/blood-2019-122824

Published: 2019

Journal Articles

Dose Reduction or Omission of Vinca Alkaloids during Initial Chemotherapy Treatment Does Not Impact Outcomes in Patients with Lymphoma

Neelam Mistry, MD, Diana Abbott, PhD, Japera Walker Wilkison, MA, Ajay Major, MDMBA, Brad M. Haverkos, MDMPH,MS, Manali Kamdar, MD

Blood (2019) 134 (Supplement_1): 4126.

https://doi.org/10.1182/blood-2019-129208

Published: 2019

Journal Articles

Bleomycin Use in the Treatment of Hodgkin Lymphoma (HL): Toxicity and Outcomes in the Modern Era

Kekoa Taparra, PhD, Heshan Liu, PhD, Mei-Yin Polley, PhD, Kay M. Ristow, BS, Thomas M. Habermann, MD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 4038.

https://doi.org/10.1182/blood-2019-121488

Published: 2019

Journal Articles

Reduction of Vertebral Bone Density in Patients with Hodgkin Lymphoma Above 30 Years of Age Correlates with the Cumulative Dose of Steroids They Receive As Part of Treatment Protocol

Nadav Ofshenko, Eyal Bercovich, Tania Mashiach, Michal Weiler-Sagie, Daniela Militianu, Eldad J Dann, MD

Blood (2019) 134 (Supplement_1): 4042.

https://doi.org/10.1182/blood-2019-122675

Published: 2019

Journal Articles

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Locke J. Bryan, MD, Scott E. Smith, MD PhD, Pamela Allen, MDMSc, Carla Casulo, Brett Alan Palmer, BS, Reem Karmali, MD, Barbara Pro, MD, Denise M Scholtens, PhD, Hatice Savas, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 4029.

https://doi.org/10.1182/blood-2019-123879

Published: 2019

Journal Articles

Report on the Treatment of Hodgkin Lymphoma with ABVD Chemotherapy at Two Rural District Hospitals in Rwanda

Cyprien Shyirambere, MD, Rebecca Deboer, MD, Yvan Butera, MD, Caitlin Driscoll, resident, Jean Bosco Bigirimana, Francois Regis Uwizeye, Temidayo Fadelu, MD, Paul H Park, MD, Alan Paciorek, Leslie E. Lehmann, MD, Lawrence N. Shulman, MD

Blood (2019) 134 (Supplement_1): 4053.

https://doi.org/10.1182/blood-2019-130780

Published: 2019

Journal Articles

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study

Blood (2019) 134 (Supplement_1): 4026.

https://doi.org/10.1182/blood-2019-124116

Published: 2019

NARROW

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Patterns of Care and Predictors of Survival in Adolescents and Young Adults with Hodgkin Lymphoma: A Population-Based Study

Health-Related Quality-of-Life Outcomes in Patients with Classical Hodgkin Lymphoma: A Prospective, Observational Study in US Oncology Practices

Late Effects Are Important Considerations in Initial Hodgkin Lymphoma Treatment Decision-Making According to Survivors

Exploring the Potential of Shallow Whole-Genome Sequencing for Diagnosis and Disease Monitoring of Lymphoma in Liquid Biopsy

Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study

Impact of Competing Treatment Scenarios on Lifetime Disease Burden and Quality Adjusted Life Expectancy (QALE) Among Survivors of High-Risk Childhood Hodgkin Lymphoma (HR-HL): A Modeling Study Based on the St. Jude Lifetime (SJLIFE) Cohort

Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT?

Dose Reduction or Omission of Vinca Alkaloids during Initial Chemotherapy Treatment Does Not Impact Outcomes in Patients with Lymphoma

Bleomycin Use in the Treatment of Hodgkin Lymphoma (HL): Toxicity and Outcomes in the Modern Era

Reduction of Vertebral Bone Density in Patients with Hodgkin Lymphoma Above 30 Years of Age Correlates with the Cumulative Dose of Steroids They Receive As Part of Treatment Protocol

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Report on the Treatment of Hodgkin Lymphoma with ABVD Chemotherapy at Two Rural District Hospitals in Rwanda

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only